I think that's a fair comment. The non-commercial character of the scheme was something that was set out in what is referred to as the chairman's statement, and that, by definition of the General Council decision in the Patent Act, was incorporated into the Canadian legislation because we thought it was an important element of the whole scheme that was created at the WTO.
So it is an important element and it runs through our legislation as it exists prior to Bill C-393. It's reflected in the provisions whereby the Federal Court can review an authorization to see whether, at the price the drug is being exported, it is for a non-commercial purpose or at a commercial price as opposed to a “humanitarian price”. It was an important element in the scheme, yes.